3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
93
Carcinoma, Non-Small-Cell Lung
46
Neoplasms
33
Carcinoma, Renal Cell
24
Neoplasm Metastasis
16
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
12
Small Cell Lung Carcinoma
9
Prostatic Neoplasms
9
Lung Neoplasms
9
Diabetes Mellitus, Insulin-Dependent, 12
9
Advanced Cancer
9
Squamous Cell Carcinoma of Head and Neck
8
Uveal Melanoma
7
Stomach Neoplasms
7
Skin Neoplasms
7
Mesothelioma
7
Kidney Neoplasms
7
Carcinoma, Transitional Cell
7
Recurrence
6
Pancreatic Neoplasms
6
Liver Neoplasms
6
Triple Negative Breast Neoplasms
5
Sarcoma
5
Ovarian Neoplasms
5
Head and Neck Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Solid Tumor
4
Interventions
human papillomavirus vaccine, L1 type 16, 18
3
valrubicin
1
ledipasvir, sofosbuvir drug combination
1
hepatitis C immune globulin, human
1
halofantrine
1
VP-102
1
Therapies, Investigational
1
Papillomavirus Vaccines
1
Oncolytic Virotherapy
1
Mitomycin
1
Ipilimumab
1
Interferons
1
Influenza Vaccines
1
Immunoglobulin G
1
Imiquimod
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Gemcitabine
1
Gels
1
Drug Therapy
1
Cantharidin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Virus Diseases
×
Ipilimumab
×
Clear all
NCT03408587
2023-05-06
CLEVER
Viralytics
Phase 1
Completed
11 enrolled